Speaker: Professor John S. Kuo, Inaugural Chair and Professor, Department of Neurosurgery, Surgical Director, Mulva Clinic for the Neurosciences, Dell Medical School, The University of Texas at Austin, USA

Precision-targeted therapies have advanced cancer treatment, but often fail because of cancer’s genetic heterogeneity. Alkylphosphocholine (APC) analogs is a newly discovered family of artificial membrane phospholipid ether that show preferential uptake and retention by many caners. Labeled and modified APC agents can detect cancer cells throughout the body, fluorescently visualise cancer, and deliver target therapies. This broad cancer detection and therapy platform is now in clinical trials.

Registration & breakfast at 7.10am, talk begins at 7.40am.